サービス不足の患者における予防的薬剤遺伝検査 (TOPP UP) の試験: ランダム化制御試験の参加者の研究枠組みとベースラインの特徴
Angel M Miranda1, Christelle Lteif1, Irina Fofanova1
1Department of Pharmacotherapy and Translational Research, UF College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Clinical and translational science
|February 23, 2026
まとめ
予防的な薬剤遺伝検査は,医療が不足している人群で実現可能である. この研究では,薬剤の満足度と処方者の受け入れに対するその影響を評価し,臨床実施の改善の可能性を示しました.
科学分野:
- 薬剤遺伝学 薬剤遺伝学について
- クリニカル・インプリメンテーション・サイエンス・サイエンス
- 健康格差 研究 研究
背景:
- 薬剤遺伝学 (PGx) はパーソナライズド医療の利点を提供しているが,臨床統合は限られている.
- 医学的に恵まれない人口は,予防的なPGx検査から著しく利益を得ることができますが,その影響はまだ十分に研究されていません.
- PGxの実現可能性と有効性を,多様なサービス不足のプライマリーケア環境で評価することは極めて重要です.
研究 の 目的:
- 医学的に不足している患者で予防的な薬剤遺伝検査を実施する可能性を評価する.
- 予防的な薬剤遺伝検査が患者の薬剤摂取満足度に与える影響を判断する.
- 薬剤遺伝学的臨床意思決定支援ツールの処方医の受容性を評価する.
主な方法:
- ランダム化され,コントロールされ,実用的な臨床試験で,サービス不足の集団のプライマリケア患者を対象とした.
- 参加者はランダムに選択され,予防的な薬剤遺伝学パネルテストまたは標準的なケアを受けた.
- アウトカムには,患者による治療満足度報告と,処方医による意思決定支援の受け入れ率が含まれていました.
主要な成果:
- この研究では,医療が十分に提供されていない多様な患者集団を成功裏に採用しました.
- 登録された参加者のベースラインの特徴が提示され,研究コホートが強調されています.
- 手稿は,将来の分析のための研究設計の概要を提供します.
結論:
- 予防的な薬剤遺伝検査は,サービス不足のプライマリーケア施設で臨床実施の有望性を示しています.
- さらなる分析により,患者の薬物使用満足度と処方箋の採用への影響が決定されます.
- この試験の設計は,健康の平等のためのPGxの有用性を理解する際の重要なギャップを解決します.
さらに関連する動画
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.8K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
11.2K
関連する概念動画
01:27Principles of Pharmacogenetics: Types of Genetic Variants
31
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
31
01:29Pharmacogenomics: Identification of New Drug Targets
49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
45
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
26
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
01:27Pharmacogenetics of Drug Metabolism: Overview
62
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
62
01:29Pharmacogenetics and Pharmacogenomics: Overview
51
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
51